Rare disease leader, Shire Pharmaceuticals, officially opened their new London office in Paddington on Monday 19 December. This office will become a centre for their UK-based employees to strengthen their relationships with stakeholders in academic research, clinical practice, regulatory affairs and medical innovation.
Hosted by Jonathan Dimbleby, we heard from Shire’s UK and Global team, including CEO Flemming Ornskov, on the important work their 22,000 global employees are doing to bring more than 40 therapies to patients in over 100 countries. Nicola Blackwood MP provided Government backing for the sector shown through the £816m invested into biomedical research centres over the next 5 years. There was also insight from Laurence Woollard, Youth Ambassador for The Haemophilia Society, on the importance of investment into rare diseases.
Operating in the UK for 30 years, Shire is now the leading global biotechnology company focused on serving people with rare diseases and highly specialised conditions. One in 17 people living in the UK will be affected by a rare disease at some point in their life and 75% of those with a rare disease are children.
Rajesh Agrawal, Deputy Mayor of London for Business, said: “London is one of the greatest scientific cities in the world and has been at the forefront of medical discovery and innovation for hundreds of years.
“I am delighted that Shire has chosen the capital for its new UK base as they look to develop treatments for some of the world’s rarest diseases. Shire clearly recognise that London is a world-leading hub for life sciences and their decision to move here is a boost for this important sector of our economy.”
To find out more about Shire Pharmaceuticals, visit their website:http://www.shirepharmaceuticals.co.uk/default.aspx